User login
Key clinical point: The third-generation tyrosine kinase inhibitor (TKI) lorlatinib demonstrated real-world safety and effectiveness in patients with advanced ROS1-rearranged (ROS1+) non–small-cell lung cancer (NSCLC) after failure of at least one ROS1 TKI.
Major finding: Median progression-free survival was 7.1 (95% CI 5.0-9.9) months and median overall survival was 19.6 (95% CI 12.3-27.5) months. The overall response rate was 45% and the disease control rate was 82%. There were no new safety signals.
Study details: The data come from a retrospective real-world LORLATU cohort study that included patients with advanced ROS1+ NSCLC (n = 80) from a French expanded access program.
Disclosures: The study was funded by French Thoracic Cancer Intergroup and Pfizer. S Baldacci, B Besse, D Moro-Sibilot, J Cadranel, V Westeel, B Roch, and J Bennouna reported ties with one or more pharmaceutical companies, including Pfizer. The other authors reported no conflicts of interest.
Source: Girard N et al. Lorlatinib for advanced ROS1+ non–small-cell lung cancer: Results of the IFCT-1803 LORLATU study. ESMO Open. 2022;7(2):100418 (Feb 25). Doi: 10.1016/j.esmoop.2022.100418
Key clinical point: The third-generation tyrosine kinase inhibitor (TKI) lorlatinib demonstrated real-world safety and effectiveness in patients with advanced ROS1-rearranged (ROS1+) non–small-cell lung cancer (NSCLC) after failure of at least one ROS1 TKI.
Major finding: Median progression-free survival was 7.1 (95% CI 5.0-9.9) months and median overall survival was 19.6 (95% CI 12.3-27.5) months. The overall response rate was 45% and the disease control rate was 82%. There were no new safety signals.
Study details: The data come from a retrospective real-world LORLATU cohort study that included patients with advanced ROS1+ NSCLC (n = 80) from a French expanded access program.
Disclosures: The study was funded by French Thoracic Cancer Intergroup and Pfizer. S Baldacci, B Besse, D Moro-Sibilot, J Cadranel, V Westeel, B Roch, and J Bennouna reported ties with one or more pharmaceutical companies, including Pfizer. The other authors reported no conflicts of interest.
Source: Girard N et al. Lorlatinib for advanced ROS1+ non–small-cell lung cancer: Results of the IFCT-1803 LORLATU study. ESMO Open. 2022;7(2):100418 (Feb 25). Doi: 10.1016/j.esmoop.2022.100418
Key clinical point: The third-generation tyrosine kinase inhibitor (TKI) lorlatinib demonstrated real-world safety and effectiveness in patients with advanced ROS1-rearranged (ROS1+) non–small-cell lung cancer (NSCLC) after failure of at least one ROS1 TKI.
Major finding: Median progression-free survival was 7.1 (95% CI 5.0-9.9) months and median overall survival was 19.6 (95% CI 12.3-27.5) months. The overall response rate was 45% and the disease control rate was 82%. There were no new safety signals.
Study details: The data come from a retrospective real-world LORLATU cohort study that included patients with advanced ROS1+ NSCLC (n = 80) from a French expanded access program.
Disclosures: The study was funded by French Thoracic Cancer Intergroup and Pfizer. S Baldacci, B Besse, D Moro-Sibilot, J Cadranel, V Westeel, B Roch, and J Bennouna reported ties with one or more pharmaceutical companies, including Pfizer. The other authors reported no conflicts of interest.
Source: Girard N et al. Lorlatinib for advanced ROS1+ non–small-cell lung cancer: Results of the IFCT-1803 LORLATU study. ESMO Open. 2022;7(2):100418 (Feb 25). Doi: 10.1016/j.esmoop.2022.100418